“Top 50 Pharma” published by Pharmaceutical Executive Magazine

  • 13,960 views
Uploaded on

Attaching herewith the report on “ Top 50 Pharma” published by Pharmaceutical Executive Magazine. Pfizer continues to be at Numero Uno position and crossed the US$ 50 billion mark in global sales …

Attaching herewith the report on “ Top 50 Pharma” published by Pharmaceutical Executive Magazine. Pfizer continues to be at Numero Uno position and crossed the US$ 50 billion mark in global sales with acquisition of Wyeth. Our own Merck KGaA is at 21st rank.
Global pharma sales growth is driven by Latin America-16.3% and 3As (Asia/Africa/Australia) – 13.3%. Europe and North America continues to witness sluggish growth.
Oncology retained its number one position in value sales by Therapeutic Classes and Lupid Regulators managed to hold on their number one position in prescriptions sales by Therapeutic Classes.
It is interesting to note that by recent estimate by PWC, Indian Domestic Pharma market would be between US$ 50-75 billion by 2020. India has plenty of catch-up to do!!!!!!!!
Hope you will enjoy reading this insightful report.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
No Downloads

Views

Total Views
13,960
On Slideshare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
0
Comments
0
Likes
8

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. 40 PHARMACEUTICAL EXECUTIVE PHARMACEUTICAL EXECUTIVE 12 TH ANNUAL PHARM EXEC 50 between two Lull The STORMS Will the recent wave of megamergers and a slow revival of biotech financing be enough to counter a looming storm surge of patent expirations? US health reform is the next big game-changer, as companies seek a balance between earning profits and placating a restive new breed of payers and the ever-expectant patient By Jerry Cacciotti and Patrick Clinton Sponsored bywww.dsm.com
  • 2. MAY 2011 www.pharmexec.com 41 Revenue Distribution of Top 50 10% Top 10 accounts for $352.5 billion in sales, 8% which is 59.40% of total revenues of the Top 50 6% Top 20 accounts for $483.8 billion in sales, which is 81.53% of total revenues of the Top 50 4% * Figures are rounded 2% 0% P Novartis Roche Sano -Aventis zer Merck GlaxoSmithKline Lilly Teva Bayer JohnsonBristol-MyersAmgen NovoIngelheim Baxter International Menarini Forest UCBCelgene Warner Chilcott Hakko Kirin Nycomed AstraZeneca & Johnson Squibb Eli Abbott Boehringer Daiichi Merck KGaAMylanChugai Genzyme CSL Otsuka Shire Cephalon Takeda AstellasEisai Sciences Nordisk Gilead Sankyo Servier Mitsubishi Tanabe Allergan Biogen Idec Alcon Watson Kyowa LundbeckShionogi Dainippon Sumitomo Apotex Actavis Hospira Stada n o ov a er - Av r t is M e t is S m Ro c k it h he s o a Z li n e Jo ec a A b ill y S q ot t E li o n b A m va Ba n Ta yer N o im N o I n gel e d a ii c A s t e s k S a ll a s B a G il e a r c k is a i yo r In S ci a A na es S e lan b is C h i e r i M e nab e nz i A ll y m e M y al F o an t L O t CB C e uka ge e n e ph t Sh c r n e A ir e r C lcon Ap ed W lo n n k mi in io n o Ac ogi H o av is co a S t ex a hi u g a G e ar in r es C e il c o t de rc CS p p H ak d b e c ge ui b D a yow a L u n a t s o to m ad N y sp ir n S u K ir z ot Te nk r di vo h e ter e n c er g s en m rv KG L er s b U t io a E hn A st r K n & en s nI hn k B io l g t P n Ta h o n ko Sh N hi Me x te d r My xo ge Sa Da Wa t su G la r in ol - ini Mi eh is t K Jo Bo Br T he Pharm Exec 50 ranks the tion drugs—as P zer, fueled by its ac- mal). But the biggest single-year bump world’s largest pharmaceutical quisition of Wyeth, grew from $45.4 came at a much smaller company: The companies by global sales of pre- billion in Rx sales to $58.5 billion. Irish rm Warner Chilcott last year ac- scription drugs—a key indicator of Meanwhile, consolidation in the ranks quired the pharmaceutical business of market change. After last year’s storm continues to place a premium on size Procter & Gamble, including the bil- of activity, the 50 set a more placid and scale: This was the rst year that it lion-dollar drug Actonel, and raised its pace, as major players worked on inte- took $2 billion in Rx revenues to join Rx revenues a whopping 111 percent to grating blockbuster mergers and licked the 50. As recently as 10 years ago, you $2.9 billion. their wounds after the latest round of could make the list with revenues of Looming over the year—and the Phase III failures. Late-phase problems only $500 million. decade—is the shadow of US health- are nothing new, and drug candidates Overall, the 50 accounted for care reform. Many in pharma feel they can come back from them, but there $593.4 billion in human prescription have dodged the bullet of new regula- was something particularly heartbreak- drug sales in 2010. That represents an tion and stand to gain as a projected ing about the recent crop of dead ends, increase of nearly 8 percent from 2009, 30 million previously uninsured Amer- given the huge unmet medical need as- when the total was $550.5 billion. But icans nally obtain insurance coverage sociated with these therapies: P zer’s among the top 10, there was slightly for healthcare. But the Patient Protec- Dimebon and Lilly’s Semagacestat for better growth. This year’s group grew tion and Affordable Care Act is not the Alzheimer’s, Merck’s vicriviroc for HIV, its Rx revenues from $319.4 billion in end of the discussion—it’s more like and Roche’s ocrelizumab for rheuma- scal 2009 to $352.5 last year—an in- the beginning of an avalanche. The toid arthritis, to name just a few. crease of over 10 percent. economic forces it sets in motion today Change was most visible on the A good percentage of that growth will be playing out for payers, patients, macro level. The list of the top 10 com- was fueled by mergers and acquisi- providers, and pharma for the foresee- panies was shaken up a bit, with No- tions. In addition to P zer and its 29 able future, changing the way care is vartis passing Sano -Aventis to move percent increase, big gainers included delivered and paid for, creating numer- into second place, and Merck jumping Merck (58 percent growth after its ous business threats, but, with luck, from seventh to fourth. It was also the merger with Schering Plough) and Ab- ending up with the possibility of get- rst year the top company crossed the bott (up nearly 28 percent in the wake ting a better alignment between help- $50 billion mark in sales of prescrip- of its acquisitions of Solvay and Pira- ing the patient and earning a pro t. Sponsored bywww.dsm.com
  • 3. 42 PHARMACEUTICAL EXECUTIVE 2011 Company 2010 Rx Sales (USD 2010 R&D spend 2010 Top-Selling Drugs Rank HQ [website] billions) [% change from 2009] (USD millions) [USD billions] Lipitor [10.7] Pfizer 1 New York, New York [pfizer.com] $58.5 [28.9%] $9,413 Enbrel [3.3] Lyrica [3.1] Diovan/Co-Diovan [6.1] Novartis 2 Basel, Switzerland [novartis.com] $42.0 [9.2%] $7,100 Gleevec/Glivec [4.3] Lucentis [1.5] Lantus [4.7] Sanofi-Aventis 3 Paris, France [sanofi-aventis.com] $40.3 [–4.1%] $5,147 Lovenox [3.7] Taxotere [2.8] Merck Singulair [5.0] 4 Whitehouse Station, New Jersey [merck.com] $39.8 [58.0%] $11,000 Remicade [2.7] Januvia [2.4] Avastin [6.8] Roche 5 Basel, Switzerland [roche.com] $39.1 [4.1%] $8,612 MabThera/Rituxan [6.7] Herceptin [5.7] Seretide/Advair [7.9] GlaxoSmithKline 6 Brentford, England [gsk.com] $36.2 [–4.2%] $6,126 Pandemic Flu Vaccine [1.8] Flixotide/Flovent [1.2] Crestor [5.7] AstraZeneca 7 London, England [astrazeneca.com] $33.3 [1.4%] $4,200 Nexium [5.0] Seroquel [4.1] Remicade [4.6] Johnson & Johnson 8 New Brunswick, New Jersey [jnj.com] $22.4 [–0.4%] $4,432 Procrit [1.9] Risperdal [1.5] Zyprexa [5.0] Eli Lilly 9 Indianapolis, Indiana [lilly.com] $21.1 [5.4%] $4,880 Cymbalta [3.5] Alimta [2.2] Humira [6.5] Abbott 10 Abbott Park, Illinois [abbott.com] $19.9 [27.7%] $3,724 Trilipix/TriCor [1.6] Kaletra [1.3] Sources: corporate data (10K’s, annual reports, etc.) and Pharm Exec estimates N/A = Not Available/Not Applicable * Estimate Figures are rounded How the listings were compiled: Companies in the Pharm Exec 50 are ranked according to global human prescription drug sales. As far as company documentation allows, generics and vaccines are included; over-the-counter products, royalties, and contract manufacturing revenue are not. In most cases, numbers are taken from annual reports or SEC filings for the fiscal year that ended in 2010. For most American and European companies, that means the year ending Dec. 31, 2010; for many Japanese companies, it means the year ending March 31, 2010. In the case of private companies that do not report results, we have made estimates based on available data, including IMS reports. For companies that report in currencies other than US dollars, we have converted their numbers using the midpoint average interbank rate for the last day of the fiscal year. Some charts that accompany this article are based on numbers from IMS Health. These are based on a different methodology and will not be consistent with the figures we have compiled from financial filings. Percentage growth figures should be treated with caution, because they can be affected by fluctuating exchange rates. Sponsored bywww.dsm.com
  • 4. 44 PHARMACEUTICAL EXECUTIVE Global Pharma Sales by Region Market Share Region USD in Billions Growth from 2009 Source: IMS Health, MIDAS North America 334.8 3.2% 29.2% Europe 230.7 1.8% Asia/Africa/Australia 98.1 13.3% Japan 85.7 0.4% 12.4% Latin America 42.0 16.3% 42.3% 10.8% Worldwide Totals: $791.4 4.2% 5.3% Sales represent audited market for pharma products only (Dec. 2009–Dec 2010) IMS figures do not account for off-invoice discounts/rebates and can vary from reported mfr sales Top 25 US Pharma Products by Sales Product 2010 2009 % Change 1 Lipitor 7.2 7.6 -5.26 2 Nexium 6.3 6.3 FLAT 3 Plavix 6.1 5.6 8.92 4 Advair Diskus 4.7 4.7 FLAT 5 Abilify 4.6 4.0 15.00 6 Seroquel 4.4 4.2 4.76 7 Singulair 4.1 3.7 10.81 8 Crestor 3.8 3.0 26.66 9 Actos 3.5 3.4 2.94 10 Epogen 3.3 3.2 3.13 11 Remicade 3.3 3.2 3.13 12 Enbrel 3.3 3.3 FLAT 13 Cymbalta 3.2 2.8 14.29 14 Avastin 3.1 3.0 3.33 15 Oxycontin 3.1 2.9 6.90 16 Neulasta 3.0 3.0 FLAT 17 Zyprexa 3.0 2.7 11.11 18 Humira 2.9 2.5 16.00 19 Lexapro 2.8 2.8 FLAT 20 Rituxan 2.8 2.6 7.69 Source: IMS Health 21 Aricept 2.5 2.3 8.7 22 Lovenox 2.3 2.8 -17.86 23 Atripla 2.2 1.9 15.79 24 Copaxone 2.2 1.7 29.41 25 Spiriva Handihaler 2.0 1.7 17.65 TOTAL US SCRIP MARKET: 2010: $307.4 2009: $300.3 2.36% Figures (rounded) in US billions Sponsored bywww.dsm.com
  • 5. 46 PHARMACEUTICAL EXECUTIVE 2011 Company 2010 Rx Sales (USD 2010 R&D spend 2010 Top-Selling Drugs Rank HQ [website] billions) [% change from 2009] (USD Millions) [USD billions] Bristol-Myers Squibb 11 New York [bms.com] $19.5 [3.6%] $3,566 Plavix [6.7] Teva 12 Petach Tikva, Israel [tevapharm.com] $16.1 [16.0%] $933 Copaxone [2.9] Amgen 13 Thousand Oaks, California [amgen.com] $14.7 [1.8%] $2,894 Neulasta/Neupogen [4.8] Bayer 14 Leverkusen, Germany [bayer.com] $14.5 [–3.6%] $2,320 Betaferon/Betaseron [1.6] Takeda 15 Osaka, Japan [takeda.com] $14.2 [–0.1%] $3,198 Actos/Glustin [4.2] Boehringer Ingelheim 16 Ingelheim, Germany [boehringer-ingelheim.com] $12.9 [–10.8%] $3,056 Spiriva [3.8] Novo Nordisk 17 Bagsvaerd, Norway [novonordisk.com] $10.8 [9.9%] $1,709 NovoRapid [2.1] Astellas 18 Tokyo, Japan [astellas.com] $10.5 [6.0%] $2,109 Prograf [1.9] Daiichi Sankyo 19 Tokyo, Japan [daiichisankyo.com] $9.8 [20.0%] $2,124 Olmesartan [2.6] Eisai 20 Tokyo, Japan [eisai.com] $8.4 [8.0%] $1,932 Aricept [3.5] Sources: corporate data (10K’s, annual reports, etc.) and Pharm Exec estimates N/A = Not Available/Not Applicable * Estimate Figures are rounded Sponsored bywww.dsm.com
  • 6. 48 PHARMACEUTICAL EXECUTIVE Top 20 Therapeutic Classes by Spending Product 2010 2009 % Change 1 Oncologics 22.3 21.5 3.72 2 Respiratory Agents 19.3 18.1 6.63 3 Lipid Regulators 18.8 18.6 1.08 4 Antidiabetes 16.9 15 12.66 5 Antipsychotics 16.1 14.7 9.52 6 Antiulcerants 11.9 14.1 -15.60 7 Antidepressants 11.6 11.5 0.87 8 Autoimmune Diseases 10.6 9.7 9.28 9 HIV Antivirals 9.2 8.2 12.19 10 Angiotensin II 8.7 8.6 1.16 11 Narcotic Analgesics 8.4 8.0 5.00 12 ADHD 7.2 6.3 14.28 13 Platelet Aggregation Inhibitors 7.1 6.5 9.23 14 Erythropoietins 6.1 6.3 -3.17 15 Multiple Sclerosis 5.7 4.9 16.33 16 Antiepileptics 5.6 6.9 -18.84 Source: IMS Health 17 Vaccines (Pure, Combo, Other) 5.0 4.6 8.69 18 Hormonal Contraceptives 4.8 4.7 2.13 19 Anti-Alzheimers 4.5 4.0 12.5 20 Immunostimulating Agents 4.2 4.1 2.44 TOTAL US SCRIP MARKET: 2010: $307.4 2009: $300.3 2.36% Figures (rounded) in USD billions Therapy Class defined using ATC-defined product groups and synthesized based on proprietary IMS Health definitons Immunostimulating Agents excludes interferons Top 20 Therapeutic Classes by Prescriptions Class 2010 2009 % Change 1 Lipid Regulators 255.4 249.7 2.28 2 Antidepressants 253.6 246.1 3.05 3 Narcotic Analgesics 244.3 241.0 1.37 4 Beta Blockers (Plain & Combo) 191.5 167.8 14.12 5 Ace Inhibitors 168.7 165.7 1.81 6 Antidiabetes 165.0 159.0 3.77 7 Respiratory Agents 153.3 152.4 0.59 8 Anti-ulcerants 147.1 145.7 0.96 9 Diuretics 131.0 131.7 -0.53 10 Antiepileptics 121.7 115.3 5.55 11 Tranquilizers 108.6 104.0 4.42 12 Thyroid Preps 107.2 105.3 1.8 13 Calcium Antagonists (Plain & Combo) 97.9 94.9 3.16 14 Antirheumatics 95.0 92.5 2.70 15 Hormonal Contraceptives 92.3 93.9 -1.70 16 Angiotensin II 83.7 84.4 -0.83 Source: IMS Health 17 Penicillins 76.1 76.6 -0.65 18 Macrolides & Similar Type 73.9 69.3 6.64 19 Vitamins & Minerals 71.9 69.8 3.01 20 Hypnotics & Sedatives 66.0 65.5 0.76 TOTAL US SCRIP MARKET: 2010: 3,995.2 2009: 3,949.2 1.16% Rx figures (rounded) in millions; Therapy classes defined using ATC defined product groups and synthesized based on proprietary IMS Health definitions Sponsored bywww.dsm.com
  • 7. 50 PHARMACEUTICAL EXECUTIVE 2011 Company 2010 Rx Sales (USD 2010 R&D spend 2010 Top-Selling Drugs Rank HQ [website] billions) [% change from 2009] (USD Millions) [USD billions] Merck KGaA 21 Darmstadt, Germany [merck.de] $7.8 [–0.4%] $1,547 Rebif [2.2] Gilead Sciences 22 Foster City, California [gilead.com] $7.4 [14.2%] $1,073 Atripla [3.0] Baxter International 23 Deerfield, Illinois [baxter.com] $5.6 [1.3%] $915 Advate [1.7] Mylan 24 Canonsburg, Pennsylvania [mylan.com] $5.2 [7.5%] $282 EpiPen [0.3] Servier 25 Neuilly-sur-Seine [servier.com] $4.9 [6.6%] $1,226 Coversil [1.5*] Chugai 26 Tokyo, Japan [chugai-pharm.co.jp] $4.6 [1.3%] $671 Avastin [0.6] Mitsubishi Tanabe 27 Osaka, Japan [mt-pharma.co.jp] $4.4 [2.4%] $897 Remicade [0.5] Menarini 28 Florence, Italy [menarini.com] $4.0* [0.2%] N/A Migard/Allegro [0.1*] Genzyme 29 Cambridge, Massachusetts [genzyme.com] $4.0 [2.3%] $847 Cerezyme [0.7] Allergan 30 Irvine, California [allergan.com] $4.0 [7.9%] $805 Botox [1.4] Sources: corporate data (10K’s, annual reports, etc.) and Pharm Exec estimates N/A = Not Available/Not Applicable * Estimate Figures are rounded Sponsored bywww.dsm.com
  • 8. MAY 2011 www.pharmexec.com 51 Top 25 Corporations by U.S. Sales Product 2010 2009 % Change 1 Pfizer 26.2 27.8 -5.75 2 Merck 18.8 19.8 -5.05 3 AstraZeneca 18.3 18.3 FLAT 4 Novartis 15.7 13.2 18.94 5 Lilly 14.3 13.2 8.33 6 Roche 13.8 14.2 -2.82 7 Teva 13.7 12.1 13.22 8 GlaxoSmithKline 13.6 15.0 -9.33 9 Johnson & Johnson 12.9 12.8 0.78 10 Amgen 12.7 12.5 1.60 11 Abbott 10.8 10.6 1.89 12 Sanofi-Aventis 10.4 11.2 -7.14 13 Bristol-Myers Squibb 9.7 9.0 7.77 14 Boehringer Ingelheim 6.4 7.6 -15.79 15 Takeda 6.0 7.9 -24.05 16 Forest 4.7 4.4 6.82 Source: IMS Health 17 Mylan 4.7 3.9 20.51 18 Gilead 4.7 3.9 20.51 19 Otsuka America 4.6 4.0 15.00 20 Eisai 4.6 4.4 4.54 21 Novo Nordisk 4.5 3.7 21.62 22 Watson 3.3 3.2 3.12 23 Nestle S.A. 3.2 2.8 14.28 24 Purdue 3.2 3.0 6.67 25 Galen Holdings 3.0 2.8 7.14 TOTAL US SCRIP MARKET: 2010: $307.4 2009: $300.3 2.36% Figures (rounded) in billions Top 25 Corporations by Prescriptions Corporation 2010 2009 % Change 1 Teva 639.3 629.8 1.51 2 Mylan 379.9 347.2 9.41 3 Novartis 265.3 240.9 10.13 4 Pfizer 242.0 265.7 -8.92 5 Watson 233.6 235.1 -0.64 6 Endo 141.0 114.5 23.14 7 Lupin 134.0 96.2 39.29 8 Merck 104.2 123.3 -15.49 9 Amneal 97.9 67.5 45.04 10 AstraZeneca 86.8 93.8 -7.46 11 Covidien 80.2 91.2 -12.06 12 GlaxoSmithKline 72.6 78.2 -7.16 13 Boehringer Ingelheim 71.1 72.4 -1.79 14 Actavis U.S. 68.1 71.1 -4.22 15 Dr Reddy 63.5 73.5 -13.60 16 Abbot 58.1 61.0 -4.75 Source: IMS Health 17 Zydus 53.9 34.9 54.44 18 Lilly 49.5 49.8 -0.60 19 West Ward 45.2 34.3 31.78 20 Forest 44.3 46.2 -4.11 21 Ranbaxy 42.5 31.0 37.09 22 Bristol-Myers Squibb 42.2 44.1 -4.31 23 Par 40.2 48.2 -16.60 24 Sanofi-Aventis 40.0 42.1 -4.99 25 Aurobindo 39.7 38.9 2.06 TOTAL US SCRIP MARKET: 2010: 3,995.2 2009: 3,949.2 1.16% Figures (rounded) in millions Top 25 U.S. Pharma Products by Prescriptions Product 2010 2009 % Change 1 hydrocodone/acetaminophen 131.2 128.2 2.34 2 simvastatin 94.1 83.8 12.29 3 lisinopril 87.4 82.8 5.56 4 levothyroxine sodium 70.5 66.0 6.82 5 amlodipine besylate 57.2 51.3 11.5 6 omeprazole (RX) 53.4 45.4 17.62 7 azithromycin 52.6 53.8 -2.23 8 amoxicillin 52.3 52.4 -0.19 9 metformin HCL 48.3 44.3 9.03 10 hydrochlorothiazide 47.8 47.9 -0.21 11 alprazolam 46.3 43.9 5.47 12 Lipitor 45.3 51.7 -12.38 13 furosemide 43.4 43.5 -0.23 14 metoprolol tartrate 38.9 41.1 -5.35 15 zolpidem tartrate 38.0 35.1 8.26 16 atenolol 36.3 39.3 -7.63 Source: IMS Health 17 sertraline HCL 35.7 34.2 4.38 18 metoprolol succinate 33.0 26.9 22.68 19 citalopram HBR 32.1 27.1 18.45 20 warfarin sodium 32.0 31.6 1.27 21 oxycodone/acetaminophen 31.9 30.2 5.63 22 ibuprofen (Rx) 31.1 30.3 2.64 23 Plavix 29.5 29.9 -1.34 24 gabapentin 29.3 25.4 15.35 25 Singulair 28.7 28.6 0.35 TOTAL US SCRIP MARKET: 2010: 3,995.2 2009: 3,949.2 1.16% Figures (rounded) in millions Sponsored bywww.dsm.com
  • 9. 52 PHARMACEUTICAL EXECUTIVE 2011 Company 2010 Rx Sales (USD 2010 R&D spend 2010 Top-Selling Drugs Rank HQ [website] billions) [% change from 2009] (USD Millions) [USD billions] Forest 31 New York, New York [frx.com] $3.9 [7.4%] $1,054 Lexapro [2.3] CSL 32 Victoria, Australia [csl.com.au] $3.8 [–3.6%] $272 N/A [N/A] UCB 33 Brussels, Belgium [ucb.com] $3.7 [–4.0%] $1,044 Keppra [1.2] Otsuka 34 Tokyo, Japan [www.otsuka.co.jp/en/] $3.6* [–46.1%] N/A Abilify [4.5*] Celgene 35 Summit, New Jersey [celgene.com] $3.5 [36.7%] $1,128 Revlimid [2.5] Biogen Idec 36 Weston, Massachusetts [biogenidec.com] $3.5 [10.1%] $1,249 Avonex [3.5] Shire 37 Dublin, Ireland [shire.com] $3.1 [16.1%] $662 Vyvanse [0.6] Alcon 38 Hünenberg, Switzerland [alcon.com] $3.1 [14.5%] $747 Glaucoma products [1.3] Warner Chilcott 39 Dublin, Ireland [wcrx.com] $2.9 [111.0%] $147 Actonel [1.0] Cephalon 40 Frazer, Pennsylvania [cephalon.com] $2.8 [28.3%] $440 Provigil [1.1] Sources: corporate data (10K’s, annual reports, etc.) and Pharm Exec estimates N/A = Not Available/Not Applicable * Estimate Figures are rounded Sponsored bywww.dsm.com
  • 10. 54 PHARMACEUTICAL EXECUTIVE Top US Patent Expiries Rank Product/Company LOE date 2010 Sales Total Rx 2010 1 LIPITOR/Pfizer Q4 2011 7,244.1 45.8 2 ADVAIR DISKUS/GSK Q3 2011 4,711.4 19.7 3 ZYPREXA/Eli Lilly Q4 2011 2,957.6 5.3 4 LEVAQUIN/Ortho-McNeil Q2 2011 1,522.4 10.9 5 XALATAN/Pfizer Q1 2011 710.8 6.9 Source: IMS Health 6 FEMARA/Novartis Q2 2011 681.6 1.3 7 ZYPREXA ZYDIS/Eli Lilly Q4 2011 331.1 0.4 8 ADVAIR HFA/GSK Q3 2011 254.6 1.1 9 PATANOL/Alcon Q2 2011 241.1 2.3 10 PATADAY/Alcon Q2 2011 215.0 2.1 11 VIVELLE-DOT/Novogyne Q1 2011 215.0 3.2 Sales figures (rounded) in USD millions; Rx figures rounded LOE = Loss of Exclusivity Top 20 Global Therapy Classes by Sales Product 2010 % Change 1 Oncologics 56.0 6.7 2 Lipid Regulators 36.4 2.0 3 Respiratory Agents 35.8 7.0 4 Antidiabetics 34.4 12.2 5 Antiulcerants 27.2 -6.7 6 Angiotensin II Antagonists 26.6 4.5 7 Antipsychotics 25.4 9.0 8 Autoimmune Agents 20.7 14.7 9 Antidepressants 20.2 3.4 10 HIV Antivirals 15.4 13.2 14.6 1.5 Source: IMS Health, MIDAS 11 Platelet Aggreg. Inhibitors 12 Antiepileptics 12.6 -3.3 13 Narcotic Analgesics 12.0 6.4 14 Cephalosporins & Combs 11.6 5.8 15 Erythropoietin Products 10.6 -1.8 16 Vaccines 10.5 3.5 17 Multiple Sclerosis 9.8 13.9 18 Antirheumatics (Non-steroid) 9.8 3.6 19 Hormonal Contraception 9.5 5.3 20 Calcium Antagonists 9.2 -8.8 TOTAL US SCRIP MARKET: 2010: $408.3 2009: $384.9 6.10% Figures (rounded) in USD billions (Dec 2009–Dec 2010) Sales represent audited market for pharma products only IMS figures do not account for off-invoice discounts/rebates and can vary from reported mfr sales Top 20 Leading Global Products by Sales Product 2010 % Change 1 Lipitor (atorvastatin) 12,656.1 -6.2 2 Plavix (clopidogrel) 8,816.5 -3.4 3 Seretide (fluticasone/salmeterol) 8,468.6 4.4 4 Nexium (esomeprazole) 8,361.5 1.3 5 Seroquel (quetiapine) 6,815.6 13.2 6 Crestor (rosuvastatin) 6,796.3 24 7 Enbrel (etanercept) 6,167.2 5.2 8 Remicade (infliximab) 6,038.6 10.3 9 Humira (adalimumab) 5,959.5 19.7 10 Zyprexa (olanzapine) 5,736.3 6.6 Source: IMS Health, MIDAS 11 Avastin (bevacizumab) 5,532.2 11.1 12 Singulair (montelukast) 5,465.4 9.1 13 Abilify (aripiprazole) 5,430.3 16.3 14 Mabthera (rituximab) 5,033.2 7.8 15 Lantus (insulin glargine) 4,685.3 16.7 16 Aricept (donepezil) 4,432.1 8.5 17 Actos (pioglitazone) 4,317.3 3.9 18 Lovenox (enoxaparin sodium) 4,282.0 -5.3 19 Herceptin (trastuzumab) 4,165.1 6.7 20 Diovan (valsartan) 4,156.4 3.5 TOTAL US SCRIP MARKET: 2010: $123,315.5 2009: 116,221.7 6.10% Increase Figures (rounded) in USD millions (Dec. 2009–Dec. 2010) Sales represent audited market for pharma products only Figures do not account for off-invoice discounts/rebates and can vary from reported mfr sales Sponsored bywww.dsm.com
  • 11. 56 PHARMACEUTICAL EXECUTIVE 2011 Company 2010 Rx Sales (USD 2010 R&D spend 2010 Top-Selling Drugs Rank HQ [website] billions) [% change from 2009] (USD Millions) [USD billions] Watson 41 Corona, California [watson.com] $2.6 [27.0%] $296 CNS generics [0.9] Lundbeck 42 Copenhagen, Denmark [lundbeck.com] $2.6 [–0.6%] $542 Cipralex/Lexapro [1.5] Kyowa Hakko Kirin 43 Tokyo, Japan [kyowa-kirin.co.jp] $2.6 [14.7%] $429 Nesp/Espo [0.6*] Dainippon Sumitomo 44 Osaka, Japan [ds-pharma.co.jp] $2.6 [20.1%] $554 Amlodin [0.6] Shionogi 45 Osaka, Japan [shionogi.co.jp] $2.4* [35.2%] $135 Crestor [0.3] Actavis 46 Hafnarfjörður, Iceland [actavis.com] $2.4* [32.5%] N/A Oxycodone [0.4] Hospira 47 Lake Forest, Illinois [hospira.com] $2.3 [13.3%] $301 N/A [N/A] Nycomed 48 Zurich, Switzerland [nycomed.com] $2.2 [–20.2%] $281 Pantoprazole [1.2] Apotex 49 North York, Ontario, Canada [apotex.com] $2.1* [–19.2%] N/A N/A [N/A] Stada 50 Bad Vilbel, Germany [stada.de] $2.1 [–5.0%] $73 Generic omeprazole [0.1] Sources: corporate data (10K’s, annual reports, etc.) and Pharm Exec estimates N/A = Not Available/Not Applicable * Estimate Figures are rounded TOTALS: 2010: $593.4 billion 2009: $550.5 billion 7.79% Sponsored bywww.dsm.com
  • 12. 58 PHARMACEUTICAL EXECUTIVE The Top 10 Year In Review 1. Pfizer President and CEO 4. Merck Elected Kenneth Frazier CEO. EU. Kombiglyze XR, the only once-daily Jeff Kindler retired, succeeded by Ian C. Bought Inspire for $430 million. Rotateq dose of DPP4/metformin, developed with Read. George Lorch elected Non-Execu- vaccine awarded top honor at Prix Galien Bristol-Myers Squibb, also approved in tive Chairman of the Board. Sutent ap- USA 2010. Merck BioVentures entered into US. Nine molecules in Phase III trials or proved in EU for treatment of pancreatic an alliance with Parexel for biosimilar devel- submitted for regulatory approval, with neuro-endocrine tumors. Launched opment. Signed commercialization agree- another 92 projects in development. Com- Prevnar 13, a vaccine against 13 strains ment with Lundbeck for Sycrest and a letter pleted deal with Rigel for development of of pneumococcal diseases in infants of mutual intent with China’s Sinopharm. fostamatinib (rheumatoid arthritis). and young children. Also has 118 Pipeline has more than 20 late-stage can- products in the R&D pipeline and had didates. Licensed oral mTOR inhibitor for 1,300 clinical trials in 2010. multiple cancers from Ariad. Oral hepatitis 8. Johnson & Johnson Completed C protease inhibitor Boceprevir granted tender offer for Crucell N.V. in February Priority Review status by FDA. 2011; acquired 98.93 percent of shares. 2. Novartis Completed purchase Products under regulatory review include: of Alcon from Nestlé for $38.7 billion. Rivaroxoban for stroke prevention in pa- Jonathan Symonds promoted to CFO. 5. Roche Rituxan approved in US as tients with atrial fibrillation (US), Telaprevir David Epstein replaced CEO Joe Jimenez first-line treatment for chronic lymphocytic for hepatitis C (US and EU), Abiraterone as Division Head, Pharmaceuticals. leukemia (CLL) and relapsed/refractory acetate for metastatic advanced prostate Thirteen major pharmaceutical approvals CLL. Tarceva approved in US and EU (US and EU), and rilpivirine for HIV. Eight in the US, Europe, and Japan, with 147 for first-line treatment of non-small-cell more candidates planned for regulatory products in development. Tasigna was ap- lung cancer after chemotherapy. FDA submission from 2011 to 2013. proved in the US, the EU, Japan, and Swit- rejected use of Avastin as a treatment zerland for patients with newly diagnosed for metastatic breast cancer; Roche Philadelphia chromosome-positive chronic has requested a hearing to appeal this 9. Eli Lilly Completed acquisition of myeloid leukemia (Ph+ CML), a form of decision. Daniel O’Day appointed COO of Alnara and Avid Radiopharmaceuticals. blood cancer. Menveo (vaccine against the Pharmaceuticals division. Alan Hippe Launched statin Livalo in the US with part- meningococcal disease) launched in the named CFO. Jean-Jacques Garaud ner Kowa. Has 68 molecules in develop- US, EU, and parts of Latin America and appointed Head of Roche Pharma ment. Several monoclonal antibodies for Asia. Sandoz launched generic enoxaparin, Research and Early Development. cancer in late-stage development. Phase its most successful launch to date, and III candidates include Necitumumab acquired Oriel Therapeutics. for non-small-cell lung cancer and Ramu- 6. GlaxoSmithKline Benlysta cirumab for metastatic breast and gastric (belimumab, the first new lupus treatment cancers. Signed commercialization deal 3. Sanofi-Aventis Initiated in 60 years) approved by FDA in March. Six with Acrux for newly approved experimen- acquisition of Genzyme for $16.6 billion products in total approved by US and EU; tal testosterone solution Axiron. (completed in April) and finished seven more filed with regulators. Malaria acquisition of OTC company Chattem. vaccine in Phase III trials in Africa, with Began collaboration programs with 30 other late-stage assets. Julian Heslop 10. Abbott The year was marked by Harvard and Columbia Universities retired as CFO, succeeded by Simon acquisitions, including the pharmaceuti- and a research alliance with Scripps Dingemans. Patents for active ingredients cal business of Solvay for $6.1 billion Genomic Medicine. Jevtana approved in Seretide/Advair expired. plus milestones, and Piramal Healthcare’s in US for second-line treatment of Healthcare Solutions business, a leader metastatic hormone-refractory in the Indian branded generics market, for prostate cancer. 7. AstraZeneca Crestor substance $2.2 billion in cash, plus $1.6 billion in patent upheld in US court. Approvals annual payments through 2014. Additional include Vimovo (naproxen/esomeprazole acquisitions included Advanced Medical Op- magnesium) in US and EU and Brilique tics, STARLIMS Technologies (informatics), (atherothrombotic event prevention) in and the remaining shares of Facet Biotech. About the Authors Jerry Cacciotti is a Partner in Oliver Wyman’s Health and Life Sciences Patrick Clinton is Marketing Director in the Health & Life Sciences practice Practice. He can be reached at Jerry.Cacciotti@oliverwyman.com of Oliver Wyman. He can be reached at Patrick.Clinton@oliverwyman.com Sponsored bywww.dsm.com